Delving into the Latest Updates on Conjugated linoleic acid with Synapse

Overview

Basic Info

Drug Type

Unknown

Synonyms

CLA

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsEndocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Advanced Malignant Solid NeoplasmObesity

Originator Organization

University of Uppsala

Active Organization-

Inactive Organization

Dartmouth-Hitchcock Medical Center

University of Uppsala

License Organization-

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

Colorectal cancer (CRC) represents the third most common cancer worldwide. Consequently, there is an urgent need to identify novel preventive and therapeutic strategies for CRC. This study aimed to screen for beneficial bacteria that have a preventive effect on CRC and to elucidate the potential mechanisms. Initially, we compared gut bacteria and bacterial metabolites of healthy volunteers and CRC patients, which demonstrated that intestinal conjugated linoleic acid (CLA), butyric acid, and Bifidobacterium in CRC patients were significantly lower than those in healthy volunteers, and these indicators were significantly negatively correlated with CRC. Next, spontaneous CRC mouse model were conducted to explore the effect of supplemental CLA-producing Bifidobacterium on CRC. Supplementation of mice with CLA-producing Bifidobacterium breve CCFM683 and B. pseudocatenulatum MY40C significantly prevented CRC. Moreover, molecular approaches demonstrated that CLA and the CLA-producing gene, bbi, were the key metabolites and genes for CCFM683 to prevent CRC. Inhibitor intervention results showed that PPAR-γ was the key receptor for preventing CRC. CCFM683 inhibited the NF-κB signaling pathway, up-regulated MUC2, Claudin-1, and ZO-1, and promoted tumor cell apoptosis via the CLA-PPAR-γ axis. Additionally, fecal microbiota transplantation (FMT) and metagenomic analysis showed that CCFM683 up-regulated Odoribacter splanchnicus through CLA production, which then prevented CRC by producing butyric acid, up-regulating TJ proteins, regulating cytokines, and regulating gut microbiota. These results will contribute to the clinical trials of Bifidobacterium and the theoretical research and development of CRC dietary products.

01 Jun 2025·Clinical Nutrition

Omega-3 and conjugated fatty acids impact on human microbiota modulation using an in vitro fecal fermentation model

Article

Author: Relvas, João B ; Dias, Cindy ; Pintado, Manuela ; Rodríguez-Alcalá, Luís Miguel ; Salsinha, Ana Sofia ; Cima, André ; Araújo-Rodrigues, Helena

BACKGROUND & AIMSGut microbiota has been gaining increasing attention and its important role in the maintenance of a general good health condition is already established. The potential of gut microbiota modulation through diet is an important research focus to be considered. Lipids, as omega-3 fatty acids, are well known for their beneficial role on organs and corresponding diseases. However, their impact on gut microbiota is still poorly defined, and studies on the role of other polyunsaturated fatty acids, such as conjugated linoleic and linolenic acids, are even scarcer.METHODSBy using an in vitro human fermentation model, we assessed the effect of omega-3, CLA isomers, and punicic acid on microbiota modulation.RESULTSFish oil, Omega-3, and CLA samples positively impact Akkermansia spp. and Bifidobacterium spp. growth. Moreover, all the samples supported Roseburia spp. growth after 24 h of fermentation and, importantly, they were able to maintain the Firmicutes: Bacteroidetes ratio near 1. All the bioactive fatty acid samples, except Pomegranate oil, were able to significantly increase butyrate levels compared to those found in the positive control (FOS) sample. Moreover, Fish oil and Omega-3 samples were able to increase the concentration of GABA, alanine, tyrosine, phenylalanine, isoleucine, and leucine between 12 and 24 h of fermentation.CONCLUSIONSThe impact of the assessed polyunsaturated fatty acids in gut microbiota has been observed in its impact on key bacteria (Akkermansia, Bifidobacterium, and Roseburia) as well as their metabolic byproducts, including butyrate and amino acids, which could potentially play a role in modulating the gut-brain axis.

01 May 2025·Veterinary Medicine and Science

The Use of Protected Fat Supplement on Milk Production, Quality and Fatty Acid Profiles in Dairy Camels

Article

Author: Chaji, Morteza ; Mohammadabadi, Tahereh ; Davar, Siamak Amin ; Hoseini, Somayeh

ABSTRACTThis experiment was conducted to investigate the effect of the protected fat supplement of unsaturated fatty acids in dairy camels. Twenty‐eight Arab camels were fed with control diet and diets containing linolenic acid (omega‐3). The obtained results were analysed as a completely randomized design. Milk production, fat, protein and the antioxidant activity of raw milk increased by using protected fat, but ash, solids and density decreased (p < 0.05). Fat, protein, density and the antioxidant activity of fermented milk of camels increased, but solids and lactose decreased (p < 0.05). The total microbial load and population of moulds in raw and fermented milk of camels fed with protected fat decreased (p < 0.05), but the population of Lactobacillus increased (p < 0.05). The concentration of unsaturated fatty acids C18:1, C18:2 and C18:3 and conjugated linoleic acid (CLA) increased (p < 0.05). Therefore, it may be possible to use omega‐3 protected fat supplementation of 80 g per day in dairy camels feeding in the desert.

100 Deals associated with Conjugated linoleic acid

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	United States	Dartmouth-Hitchcock Medical Center	01 Mar 2010
Obesity	Phase 1	Sweden	University of Uppsala	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


DDW2022	Not Applicable	Weight Loss	-	CONJUGATED LINOLEIC ACID (CLA), COLLAGEN, AND HYALURONIC ACIDConjugated Linoleic Acid (CLA), COLLAGEN, AND HYALURONIC ACID (Conjugated Linoleic Acid (CLA))	ciaiqdamyu(zblisitzpb) = tgglnweqyp zbukkotyee (foneenynoo ) View more	-	24 May 2022
Pubmed \| Eur J Nutr	Not Applicable	Nutritional and Metabolic Diseases	-	Conjugated linoleic acid (CLA)	azxhxiadty(slidwygvmo) = pcwecfrnad ojdrhwwhtp (zjpueokqhh, -1.79 to -0.86) View more	Negative	01 Mar 2012
Pubmed \| J Nutr	Not Applicable	Obesity	-	Conjugated Linoleic Acid	(gwcdyeltbp) = tlcgdpdzdq milnywlajw (elnzylbxtp )	-	01 May 2007
Pubmed \| Int J Obes (Lond)	Not Applicable	Metabolic Syndrome \| Obesity	-	Conjugated linoleic acid (CLA)	wheqbcpjql(kcginsnfzb): P-Value = 0.04	Positive	01 Aug 2001
Pubmed \| Int J Obes (Lond)	Not Applicable	Metabolic Syndrome \| Obesity	-	Conjugated linoleic acid (CLA) (Placebo)	wheqbcpjql(kcginsnfzb): P-Value = 0.04	Positive	01 Aug 2001